Has Nataia Buza, MD received payments from drug or device companies?

Yes. Drug and device makers reported $29,457 in general payments to Nataia Buza, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nataia Buza, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nataia Buza, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nataia Buza, MD

Anatomic Pathology · New Haven, CTNPI 1790962017

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,606 of the $29,457 with a category attached, or 93.7%. Daiichi Sankyo Inc. accounts for 71.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $27,190, more than ten times the $170 reported in 2019.

$29,457in general payments, 2019–2025

Across 29 payments — averaging $1015.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$21K
Astrazeneca UK Limited$6K
Merck$1K
Agilent Technologies, Inc.$526
Foundation Medicine, Inc.$170
AstraZeneca$154
plus $218 from 2 others

What the payments were for

Consulting fees$27,60694%
Speaking & faculty fees$1541%
Travel & lodging$7833%
Food & beverage$9143%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	11	$20,901
Astrazeneca UK Limited	2	$6,205
Merck	2	$1,283
Agilent Technologies, Inc.	10	$526
Foundation Medicine, Inc.	1	$170
AstraZeneca	1	$154
Immunogen, Inc.	1	$128
GSK	1	$90

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,457 in reported general payments places this provider in the 85th percentile of 28 anatomic pathology providers in Connecticut.

See all anatomic pathology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$25,053

Medicare patients

124

Services billed

550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in New Haven

Sihem KhelifaNew Haven$169K
David RimmNew Haven$126K
Demetrios BraddockNew Haven$36K
Dhanpat JainNew Haven$22K
Carlo BifulcoNew Haven$19K
Pei HuiNew Haven$13K
Laura ManuelidisNew Haven$4K
John SinardNew Haven$2K
Jennifer Moreira-DinzeyNew Haven$252
Fattaneh TavassoliNew Haven$180

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →